Transplanted heart made more acceptable by daclizumab Daclizumab
has been found to reduce the risk of cellular rejection after a heart transplant// when used on top of standard immunosuppression.
The drug, a humanized monoclonal antibody, is directed against the interleukin-2 receptor, thereby inhibiting T-cell proliferation.
Patients who we...
Renal Transplantation in Children Younger Than 6 Years Old
...us in 39%, mycophenolate in 49% and azathioprine in 51%. A steroid-free protocol was used in 17% of the patients. In the last 21 cases, basiliximab or daclizumab
The group found that there were 13 (32.5%) graft losses. Four of these had artery/vein thromboses, 3 chronic rejections, 3 deaths, an...
daclizumab in Medical Technology
daclizumab in Biological Technology